Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May;36(3):186-193.
doi: 10.1038/s41443-023-00692-7. Epub 2023 Apr 15.

Male delayed orgasm and anorgasmia: a practical guide for sexual medicine providers

Vi Nguyen  1 , Isabella Dolendo  1 , Maria Uloko  1 , Tung-Chin Hsieh  1 , Darshan Patel  2
Affiliations
Review

Male delayed orgasm and anorgasmia: a practical guide for sexual medicine providers

Vi Nguyen et al. Int J Impot Res. 2024 May.

Abstract

Delayed orgasm (DO) is defined as increased latency of orgasm despite adequate sexual stimulation and desire. Anorgasmia (AO) is characterized as the absence of orgasm. Etiologies of DO/AO include medication-induced, psychogenic, endocrine, and genitopelvic dysesthesia. Given the multifactorial complex nature of this disorder, a thorough history and physical examination represent the most critical components of patient evaluation in the clinical setting. Treating DO/AO can be challenging due to the lack of standardized FDA-approved pharmacotherapies. There is no standardized treatment plan for DO/AO, though common treatments plans are often multidisciplinary and may include adjustment of offending medications and sex therapy. In this review, we summarize the etiology, diagnosis, and treatment of DO/AO.

PubMed Disclaimer

Conflict of interest statement

VN has no disclosures. ID has no disclosures. MU has the following to disclose: Endo Pharmaceuticals—Advisor. TCH has the following to disclose: Boston Scientific—Advisor, consultant. Endo Pharmaceuticals—Advisor, consultant. DP has the following to disclose: Acerus Pharmaceuticals—Speakers Bureau, research grant. Apta Pharma—Equity interest. Endo Pharmaceuticals—Advisor

Figures

Fig. 1
Fig. 1
Proposed algorithm to approaching the patient who presents with DO/AO.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Nimbi FM, Tripodi F, Rossi R, Navarro-Cremades F, Simonelli C. Male sexual desire: an overview of biological, psychological, sexual, relational, and cultural factors influencing desire. Sex Med Rev. 2020;8:59–91. doi: 10.1016/j.sxmr.2018.12.002. - DOI - PubMed
    1. Aboseif SR, Breza J, Orvis BR, Lue TF, Tanagho EA. Erectile response to acute and chronic occlusion of the internal pudendal and penile arteries. J Urol. 1989;141:398–402. doi: 10.1016/S0022-5347(17)40782-8. - DOI - PubMed
    1. Salonia A, Bettocchi C, Boeri L, Capogrosso P, Carvalho J, Cilesiz NC, et al. European Association of Urology Guidelines on Sexual and Reproductive Health-2021 Update: Male Sexual Dysfunction. Eur Urol. 2021;80:333–57. doi: 10.1016/j.eururo.2021.06.007. - DOI - PubMed
    1. Rambhatla A, Rajfer J. Male sexual dysfunction. In: Encyclopedia of Endocrine Diseases (Second Edition). 2018. p. 767–74.
    1. Burnett AL, Nehra A, Breau RH, Culkin DJ, Faraday MM, Hakim LS, et al. Erectile dysfunction: AUA Guideline. J Urol. 2018;200:633–41. doi: 10.1016/j.juro.2018.05.004. - DOI - PubMed

MeSH terms